Recursion Pharmaceuticals, a biotech start-up in Salt Lake City, today announced the appointment Robert Lollini, MBA, CPA, to its business advisory panel. Lollini is a distinguished leader in the life sciences, having served as President and Chief Executive Officer of IOMED, Inc. and Myrexis, Inc. Currently, Mr. Lollini serves as the Chief Financial Officer of BioFire Diagnostics, a clinical diagnostics company recently acquired by the multinational biotechnology company BioMérieux.
Dr. Dean Y. Li, Co-founder and Chief Scientific Officer of Recursion and the Vice-Dean of Research at the University of Utah Health Sciences Center adds: “Recursion is elated that Bob has joined our Business Advisory Panel. Bob has years of experience in building and running biotech companies here in the Mountain-West. His deep financial expertise, especially in the context of business-building in the life sciences, will be a tremendous asset for our growing company. His experience across a variety of aspects of biotechnology, from pharmaceutical development to diagnostics, will be invaluable as Recursion applies its technology in a variety of similar areas… I am excited personally as well, both in my Recursion and University positions, to understand at a deeper level how BioFire has so ingeniously navigated the space to become such a shining success with roots here at the University of Utah.”
Mr. Lollini added: “I was intrigued at the onset when I learned about Recursion’s technology platform. The ability to rapidly screen approved drugs and other compounds in various stages of development, for therapeutic activity against new disease targets enhances the economic feasibility of finding therapeutics to treat these rare diseases by offering significant potential benefit in reducing the time, cost and risk of development and approval. I am excited to work with Chris, Dr. Li and other members of the Advisory Board to help guide the advancement of this technological breakthrough.”
Mr. Lollini, along with several others to be announced at a later date, will advise Recursion Pharmaceuticals on a wide range of topics including business strategy and business development.
Robert Lollini, MBA, CPA. Robert has served as Chief Financial Officer of BioFire Diagnostics since October of 2012. BioFire Diagnostics is a privately held clinical diagnostics company manufacturing the FilmArray System. Prior to his work with BioFire, Mr. Lollini was the Chief Financial Officer from 2009 to 2011 and Chief Executive Officer through 2012 of NASDAQ-listed Myrexis, Inc. Mr. Lollini held a variety of executive positions at Iomed, Inc. an AMEX-traded drug delivery company between 1993 and 2007. Prior to his work with Iomed, he held various executive management positions at R.P. Scherer Corporation, a developer of oral drug delivery systems. Robert started his career with the accounting firm Arthur Anderson & Co. Mr. Lollini is a Certified Public Accountant. He received a Bachelor of Arts degree in Accounting from Michigan State University and an MBA in Finance and Economics from the University of Detroit Mercy.
Recursion is a digital biology company industrializing drug discovery. Recursion does this by combining automation, artificial intelligence, machine learning, and in vivo validation capabilities with a highly cross-functional team to discover novel medicines and expand our collective understanding of biology. Recursion’s rich, relatable database of 4 petabytes of biological images generated in-house on the company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people’s lives. Recursion is proudly headquartered in Salt Lake City. Learn more at www.recursionpharma.com or connect on www.recursionpharma.com, or connect on Twitter, Facebook, and LinkedIn.